Rena Moon1, Andre Teixeira, Kelly Potenza, Muhammad A Jawad. 1. Department of Bariatric Surgery, Orlando Regional Medical Center, Bariatric and Laparoscopy Center, Orlando Health, 89 Copeland Ave, 1st Floor, Orlando, FL 32806, USA.
Abstract
BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (RYGB) is an effective treatment for morbid obesity. Current average length of hospital stay (LOS) after RYGB is 2-3 days and 30-day readmission rate is 8-13 %. The aim of our study is to evaluate the effect of routine gastrostomy tube placement in perioperative outcomes of RYGB patients. METHODS: Between January 2008 and December 2010, a total of 840 patients underwent RYGB at our institution. All RYGB patients had gastrostomy tube placed, which was kept for 6 weeks. A retrospective review of a prospectively collected database was performed for all RYGB patients, noting the outcomes and complications of the procedure. RESULTS: Average LOS in our patient population was 1.1 days (range, 1-14 days), and 824 (98.3 %) patients were discharged on postoperative day 1. Readmissions within 30 days after the index RYGB was observed in 31 (3.7 %) patients. Reasons included abdominal pain (n = 14), nausea/vomiting (n = 6), gastrostomy tube-related complications (n = 5), chest pain (n = 3), allergic reaction (n = 1), urinary tract infection (n = 1), and dehydration (n = 1). Of these readmitted patients, nine (1.1 %) patients required reoperations due to small bowel obstruction (n = 5), perforated anastomotic ulcer (n = 1), anastomotic leak (n = 1), subphrenic abscess (n = 1), and appendicitis (n = 1). CONCLUSIONS: Routine gastrostomy tube placement in the gastric remnant at the time of RYGB seems to have contributed to our short LOS and low 30-day readmission rate.
BACKGROUND: Laparoscopic Roux-en-Y gastric bypass (RYGB) is an effective treatment for morbid obesity. Current average length of hospital stay (LOS) after RYGB is 2-3 days and 30-day readmission rate is 8-13 %. The aim of our study is to evaluate the effect of routine gastrostomy tube placement in perioperative outcomes of RYGB patients. METHODS: Between January 2008 and December 2010, a total of 840 patients underwent RYGB at our institution. All RYGB patients had gastrostomy tube placed, which was kept for 6 weeks. A retrospective review of a prospectively collected database was performed for all RYGB patients, noting the outcomes and complications of the procedure. RESULTS: Average LOS in our patient population was 1.1 days (range, 1-14 days), and 824 (98.3 %) patients were discharged on postoperative day 1. Readmissions within 30 days after the index RYGB was observed in 31 (3.7 %) patients. Reasons included abdominal pain (n = 14), nausea/vomiting (n = 6), gastrostomy tube-related complications (n = 5), chest pain (n = 3), allergic reaction (n = 1), urinary tract infection (n = 1), and dehydration (n = 1). Of these readmitted patients, nine (1.1 %) patients required reoperations due to small bowel obstruction (n = 5), perforated anastomotic ulcer (n = 1), anastomotic leak (n = 1), subphrenic abscess (n = 1), and appendicitis (n = 1). CONCLUSIONS: Routine gastrostomy tube placement in the gastric remnant at the time of RYGB seems to have contributed to our short LOS and low 30-day readmission rate.
Authors: John Saunders; Garth H Ballantyne; Scott Belsley; Daniel J Stephens; Amit Trivedi; Douglas R Ewing; Vincent A Iannace; Rafael F Capella; Annette Wasileweski; Steven Moran; Hans J Schmidt Journal: Obes Surg Date: 2008-05-02 Impact factor: 4.129
Authors: Matthew T Baker; Michael D Lara; Christopher J Larson; Pamela J Lambert; Michelle A Mathiason; Shanu N Kothari Journal: Surg Obes Relat Dis Date: 2006 Jul-Aug Impact factor: 4.734
Authors: David Goitein; Daniel J Gagné; Pavlos K Papasavas; Gordon McLean; Richard G Foster; H Scott Beasley; Philip F Caushaj Journal: Surg Obes Relat Dis Date: 2006 Nov-Dec Impact factor: 4.734
Authors: Jason T Wiseman; Amanda M Guzman; Sara Fernandes-Taylor; Travis L Engelbert; R Scott Saunders; K Craig Kent Journal: J Am Coll Surg Date: 2014-05-22 Impact factor: 6.113